Healthtech company CoMind has raised $102.5 million in total funding. The capital will advance its non-invasive brain monitoring technology. The financing includes a $60 million Series A round led by Plural, with participation from LocalGlobe and Octopus Ventures.
CoMind develops technology to measure core brain health indicators without surgery. The device can track metrics like cerebral blood flow and intracranial pressure through the skull. This offers a safe alternative to current methods that require drilling into a patient's head.
Invasive monitoring carries a 15 percent complication rate. Because of this risk, only 5 percent of the three million annual traumatic brain injury patients in the US receive the test. CoMind aims to provide accurate data to improve treatment decisions for the other 95 percent. The company will seek FDA approval for its technology within the next two years. Approval would provide access to the large US intensive care unit market.
CoMind also plans to build an AI platform that uses sensor data to predict complications and personalize patient care.
